Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 5/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25236005 | 0.87 | LPAR1 (0.47) | LPAR1HDAC1HDAC2HDAC3LMNA | |
| SCHEMBL25283551 | 0.85 | LPAR1 (0.39) | LPAR1L3MBTL1AKR1C3MEN1KMT2A | |
| SCHEMBL30472619 | 0.82 | LPAR1 (0.44) | LPAR1AKR1C3MEN1KMT2AMAPK1 | |
| SCHEMBL6491 | 0.79 | LPAR1 (0.53) | LPAR1LMNASMN1; SMN2L3MBTL1PLAU | |
| SCHEMBL30472615 | 0.78 | LPAR1 (0.48) | LPAR1 | |
| SCHEMBL30472438 | 0.78 | LPAR1 (0.51) | LPAR1SMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL25235476 | 0.78 | LPAR1 (0.51) | LPAR1SMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL22480386 | 0.77 | LPAR1 (0.75) | LPAR1AKR1C3KLKB1 | |
| SCHEMBL22467466 | 0.77 | LPAR1 (0.75) | LPAR1AKR1C3KLKB1 | |
| SCHEMBL32671664 | 0.76 | LPAR1 (0.72) | LPAR1LMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066341-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-02-27 | — | — | US | disclosed |
| EP-4452965-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023118253-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066341-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | LPAR1, LPAR2, LPAR3 | LPAR1 1/4885HDAC1 978/4885HDAC2 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.